Abstract
Aim:
The renin-angiotensin system (RAS) plays a critical role in blood pressure control and body fluid and electrolyte homeostasis. In the past few years, angio-tensin (Ang) (1–7) has been reported to counteract the effects of Ang II and was even considered as a new therapeutical target in RAS. The present study aimed to investigate the effect of Ang (1–7) administration on a diabetic animal model and the modulation on local RAS.
Methods:
Streptozotocin (STZ) injection-induced diabetic rats were used in the experiment. The animals were divided into 3 groups: (1) control; (2) STZ-induced diabetes; and (3) STZ-induced diabetes with chronic Ang (1–7) treatment [D+Ang(1–7)]. In the D+Ang(1–7) group, a dose of 25 μg·kg−1·h−1 of Ang (1–7) was continually injected through the jugular vein by embedding mini-osmotic pump for 6 weeks. Plasma glucose, ratio of kidney to body weight, and 24 h urine protein and serum creatinine were monitored by conventional measurement. Plasma and renal Ang II levels were measured by radioimmunoassay. Ang-converting enzyme (ACE), ACE2, Ang II type 1 (AT1) receptor, Ang II type 2 (AT2) receptor, Ang (1–7) Mas receptor, and TGF-β1 mRNA levels were measured by real time PCR; ACE, ACE2, and TGF-β1 protein levels were analyzed by Western blotting.
Results:
The renal function of diabetic rats was significantly retrogressed when compared with that of control rats. After the treatment by constant Ang (1–7) vein injection for 6 weeks, renal function was found to be even worse than diabetic rats, and both TGF-β1 mRNA and protein levels were elevated in the D+Ang(1–7) group compared with the diabetic rats. The real-time PCR result also showed an increase in ACE mRNA expression and decrease in ACE2 mRNA level in the D+Ang(1–7) group when compared with diabetic rats. The number of AT1 receptors increased in the Ang (1–7)-injected group, while the number of AT2 and Mas receptors decreased.
Conclusion:
Exogenous Ang (1–7) injection did not ameliorate STZ-induced diabetic rat renal injury; on the contrary, it accelerated the progressive diabetic nephropathies.
Similar content being viewed by others
Article PDF
References
Unger T, Culman J, Gohlke P . Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 1998; 16 ( Suppl 7): S3–9.
Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG, et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 2000; 58: 2320–30.
Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD . Early streptozotocin-diabetes mellitus downregulates rat kidney AT(2) receptors. Am J Physiol Renal Fluid Electrolyte Physiol 2001; 280: F254–65.
Gilbert RE, Cox A, Wu LL, Allen TJ, Hulthen L, Jerums G, et al. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of angiotensin converting enzyme inhibition. Diabetes 1998; 47: 414–22.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–9.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 2000; 87: E1–9.
Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ . A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238–43.
Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 2002; 277: 14838–43.
Harmer D, Gilbert M, Borman R, Clark KL . Quantitative mRNA expression profiling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Lett 2002; 532: 107–10.
Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41: 392–7.
Lely AT, Hamming I, van Goor H, Navis GJ . Renal ACE2 expression in human kidney disease. J Pathol 2004; 204: 587–93.
Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G . Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328–34.
Strawn WB, Ferrario CM, Tallant EA . Angiotensin2(127) reduces smooth muscle growth after vascular injury. Hypertension 1999; 33: 207–11.
García-Villalba P, Denkers ND, Wittwer CT, Hoff C, Nelson RD, Mauch TJ . Real-time PCR quantification of AT1 and AT2 angiotensin receptor mRNA expression in the developing rat kidney. Nephron Exp Nephrol 2003; 94: E154–9.
Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z . Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44: 874–7.
Fox J, Guan S, Hymel AA, Navar LG . Dietary Na and ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol 1992; 262: F902–9.
Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000; 97: 8015–20.
Santos JC, Jerez S, Peral De Bruno M, Coviello A . Angiotensin-(1–7) increases osmotic water permeability in isolated toad skin. Braz J Med Res 2000; 33: 1099–104.
Stegbauer J, Vonend O, Oberhauser V, Rump LC . Effects of angiotensin (1–7) and other bioactive components of the renin - angiotensin system on vascular resistance and noradrenaline release in rat kidney. J Hypertens 2003; 21: 1391–9.
Kennefick TM, Oyama TT, Thompson MM, Vora JP, Anderson S . Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am J Physiol 1996; 271: 595–602.
Muller C, Endlich K, Helwig JJ . Role of eicosanoids in renal angiotensin II vasoconstriction during nitric oxide blockade. Kidney Int 1998; 54 ( Suppl 67): S234–7.
Suzuki Y, Matsumura Y, Egi Y, Morimoto S . Effects of losartan, a non peptide angiotensin II receptor antagonist, on norepinephrine overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs. J Pharmacol Exp Ther 1992; 263: 956–63.
Pieper GM . Enhanced, unaltered and impaired nitric oxide-mediated endothelium-dependent relaxation in experimental diabetes mellitus: importance of disease duration. Diabetologia 1999; 42: 204–13.
Hopfner RL, McNeill RJ, Gopalakrishnan V . Plasma endothelin level and vascular responses at different temporal stages of streptozotocin diabetes. Eur J Pharmacol 1999; 374: 221–7.
Roks AJ, van Geel PP, Pinto YM, Buikema H, Henning RH, de Zeeuw D, et al. Angiotensin-(1–7) is a modulator of the human renin angiotensin system. Hypertension 1999; 34: 296–301.
Russo LM, del Re E, Brown D, Lin HY . Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes 2007; 56: 380–8.
Anderson S, Jung FF, Ingelfinger JR . Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477–86.
de Gasparo M, Levens NR . Pharmacology of angiotensin II receptors in the kidney. Kidney Int 1994; 46: 1486–91.
Douglas JG, Hopfer U . Novel aspect of angiotensin receptors and signal transduction in the kidney. Annu Rev Physiol 1995; 56: 649–69.
Edwards RM, Aiyar N . Angiotensin II receptor subtypes in the kidney. J Am Soc Nephrol 1993: 3: 1643–52.
Timmermans PB, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD . Angiotensin II receptors and functional correlates. Am J Hypertens 1992; 5: 406–10.
Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, el-Dahr SS . Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol Renal Physiol 1997; 273: F170–7.
Shanmugam S, Llorens-Cortes C, Clauser E, Corvol P, Gasc JM . Expression of angiotensin II AT2 receptor mRNA during development of rat kidney and adrenal gland. Am J Physiol Renal Fluid Electrolyte Physiol 1995; 268: F922–30.
Sharma M, Sharma R, Greene AS, McCarthy ET, Savin VJ . Documentation of angiotensin II receptors in glomerular epithelial cells. Am J Physiol Renal Physiol 1998; 274: F623–37.
XZhuo J, Maric C, Harris PJ, Alcorn D, Mendelsohn FA . Localization and functional properties of angiotensin II AT1 receptors in the kidney: focus on renomedullary interstitial cells. Hypertens Res 1997; 20: 233–50.
Siragy HM and Carey RM . The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 39, 59-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest 1996; 97: 1978–82.
Maric C, Aldred GP, Harris PJ, Alcorn D . Angiotensin II inhibits growth of cultured embryonic renomedullary interstitial cells through the AT2 receptor. Kidney Int 1998; 53: 92–9.
Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92: 10663–7.
Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM . Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 2004; 383: 45–51.
Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, Burns KD . Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 2001; 280: F254–65.
Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005; 111: 1806–13.
Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM . Converting enzyme determines plasma clearance of angiotensin-(1–7). Hypertension 1998; 32: 496–502.
Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM . Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J Hypertens 1996; 14: 799–805.
Chappell MC, Pirro NT, Sykes A, Ferrario CM . Metabolism of angiotensin-(1–7) by angiotensin-converting enzyme. Hypertension 1998; 31: 362–7.
Brosnihan KB, Li P, Ferrario CM . Angiotensin-(1–7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27: 523–8.
Benter IF, Ferrario CM, Morris M, Diz I . Antihypertensive actions of angiotensin-(1–7) in spontaneously hypertensive rats. Am J Physiol 1995; 269: H313–9.
Freeman EJ, Chisolm G, Ferrario CM, Tallant EA . Angiotensin-(1–7) inhibits vascular smooth muscle cell growth. Hypertension 1996; 28: 104–8.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by the National Natural Science Foundation of China (No 30470627).
Rights and permissions
About this article
Cite this article
Shao, Y., He, M., Zhou, L. et al. Chronic angiotensin (1–7) injection accelerates STZ-induced diabetic renal injury . Acta Pharmacol Sin 29, 829–837 (2008). https://doi.org/10.1111/j.1745-7254.2008.00812.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00812.x
Keywords
This article is cited by
-
Angiotensin(1–7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade
Kidney International (2015)
-
Adenosine 5′-triphosphate stimulates the increase of TGF-β1 in rat mesangial cells under high-glucose conditions via reactive oxygen species and ERK1/2
Acta Pharmacologica Sinica (2009)